Growth Hormone Therapy May Increase Fracture Risk in a Pubertal Patient with Osteogenesis Imperfecta

Abstract

We describe a patient with osteogenesis imperfecta type 1A who was treated with growth hormone for 9 years. The treatment resulted in a marked improvement in growth velocity, but four fractures occurred during the pubertal period.